Choose your location
Select your country or region to view content specific to your country.
Product News You can check out the latest product information
-
Obtained CE-IVD marking for Seeplex® RV12 ACE Detection
Simultaneous detection of 12 major respiratory viruses Seegene's Seeplex® RV12 ACE Detection, RV5 ACE Screening have been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
Jun 30, 2008｜ Seeplex® RV12 ACE Detection
-
Obtained CE-IVD marking for Seeplex® PneumoBacter ACE Detection
Accurately detecting 6 pneumonial bacteria at once Seegene's Seeplex® PneumoBacter ACE Detection have been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
Jun 30, 2008｜ Seeplex® PneumoBacter ACE Detection
-
Seeplex® RV12 ACE Detection: CE-IVD Marking
Seeplex® RV12 ACE DetectionSimultaneously detecting 12 major respiratory virusesSeeplex® RV 12 ACE Detection is designed to detect major respiratory viruses. The conventional methods (culture and IFA, etc.) to detect respiratory viruses take several days or do not have enough sensitivity. Therefore, many of the recently developed diagnostic methods employ PCR methods. Among them, Seegene's Respiratory Virus Detection is outstanding in terms of sensitivity and specificity by applying DPO™ technology and detects multiple respiratory viruses by Multiplex RT-PCR.
Jun 03, 2008｜ Seeplex® RV12 ACE Detection
-
Seeplex® BRAF ACE Detection: CE-IVD Marking
Seeplex® BRAF ACE DetectionBRAF mutation (V600E) DetectionSeeplex® BRAF V600E ACE Detection is designed to detect BRAF mutation (V600E) characteristic for papillary thyroid carcinoma. The BRAF gene involves in mediating cellular response to growth, differentiation and death signals in RAS RAF MEK MAP kinase pathway. BRAF mutations are common in melanoma, colon cancer, gliomas, and lung cancer. In 80% cases, it is a single substitution1),2) (V600E). Especially, in papillary thyroid carcinoma (PTC), the incidence of BRAF mutation occurs 26-69% (likely 45-50%) of all cases1),3). Seeplex® BRAF V600E ACE Detection tests BRAF mutation, the most common genetic mutation in PTC, with single PCR reaction by utilizing DPO™ technology.
Jun 02, 2008｜ Seeplex® BRAF ACE Detection
-
Seeplex® RV/PB18 ASE Detection: CE-IVD Marking
Seeplex® RV/PB18 ASE DetectionDetecting Major Respiratory PathogensSeeplex® RV/PB18 ASE Detection is designed to detect simultaneously 13 respiratory viruses and 5 pneumonia bacteria. Existing diagnostic methods have tested for some viruses and some bacteria. However, it is difficult to accurately diagnose co-infection of viruses and bacteria because until now there has been no method to detect two types using one test, and thus the proper prescription cannot be made at the appropriate time. Seegene's products make it possible to prescribe quickly in the early stage of symptoms with just one test by determining whether a respiratory infection has been caused by viruses or bacteria or both. If the influenza A or influenza B virus is detected using Seegene products, Oseltamivir or Zanamavir can be prescribed. If the respiratory syncytial virus is detected using Seegene products, Ribavirin can be prescribed. This product will help with the development of specific antiviral preparations and antibiotics in the long term, and ultimately make customized prescriptions possible. Capillary-based auto sequencers including ABI 3130/3100 are applicable for Seeplex® RV/PB18 ASE Detection.
Jun 01, 2008｜ Seeplex® RV/PB18 ASE Detection
-
Obtained CE-IVD marking for Seeplex® MTB ACE Detection
Seeplex® MTB ACE Detection Detection of M. tuberculosis (MTB) Seegene's Seeplex® MTB ACE Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
May 19, 2008｜ Seeplex® MTB ACE Detection
-
Obtained CE-IVD marking for Seeplex® MTB Nested ACE Detection
Detection of M. tuberculosis (MTB) in various specimens Seegene's Seeplex® MTB Nested ACE Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
May 19, 2008｜ Seeplex® MTB Nested ACE Detection
-
Obtained CE-IVD marking for Seeplex® MTB/BCG ACE Detection
Seeplex® MTB/BCG ACE Detection Discrimination of MTB from M. bovis BCG Seegene's Seeplex® MTB/BCG ACE Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
May 19, 2008｜ Seeplex® MTB/BCG ACE Detection